QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
OTCMKTS:IPCIF

Intellipharmaceutics International Stock Forecast, Price & News

$0.17
0.00 (0.00%)
(As of 01/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.17
$0.17
50-Day Range
$0.08
$0.20
52-Week Range
$0.08
$0.48
Volume
N/A
Average Volume
24,800 shs
Market Capitalization
$5.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.75
30 days | 90 days | 365 days | Advanced Chart
Receive IPCIF News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter.


Intellipharmaceutics International logo

About Intellipharmaceutics International

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin XR and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Headlines

Intellipharmaceutics Comments on Recent Trading Activity
December 22, 2021 |  finance.yahoo.com
Intellipharmaceutics International Inc. (IPCI.TO)
June 17, 2021 |  finance.yahoo.com
News for IntelliPharmaCeutics International Inc Registered Shs
December 30, 2020 |  markets.businessinsider.com
Intellipharmaceutics Reports Director Election Results
December 23, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:IPCIF
Employees
13
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.40 million
Book Value
($0.27) per share

Profitability

Net Income
$-3.39 million
Pretax Margin
-1,219.13%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$5.50 million
Optionable
Optionable

Company Calendar

Last Earnings
7/16/2018
Today
1/18/2022
Fiscal Year End
11/30/2022

MarketRank

Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Intellipharmaceutics International (OTCMKTS:IPCIF) Frequently Asked Questions

How has Intellipharmaceutics International's stock been impacted by COVID-19?

Intellipharmaceutics International's stock was trading at $0.1201 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IPCIF stock has increased by 38.5% and is now trading at $0.1663.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Intellipharmaceutics International?

Intellipharmaceutics International saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 2,400 shares, an increase of 380.0% from the December 15th total of 500 shares. Based on an average daily volume of 140,500 shares, the days-to-cover ratio is currently 0.0 days.
View Intellipharmaceutics International's Short Interest
.

How were Intellipharmaceutics International's earnings last quarter?

Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) posted its earnings results on Monday, July, 16th. The company reported ($0.70) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.70). The firm had revenue of $0.58 million for the quarter, compared to the consensus estimate of $0.90 million.
View Intellipharmaceutics International's earnings history
.

When did Intellipharmaceutics International's stock split? How did Intellipharmaceutics International's stock split work?

Intellipharmaceutics International's stock reverse split on the morning of Friday, September 14th 2018. The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of Intellipharmaceutics International stock prior to the reverse split would have 10 shares after the split.

Who are Intellipharmaceutics International's key executives?

Intellipharmaceutics International's management team includes the following people:
  • Dr. Isa Odidi M.B.A., Ph.D., MBA, Co-Founder, Chairman, CEO & Co-Chief Scientific Officer (Age 63, Pay $362.51k)
  • Dr. Amina Odidi, Pres, COO, Co-Chief Scientific Officer, Acting CFO & Exec. Director (Age 61, Pay $362.51k)
  • Fazayill Shaideen, Controller

What is Intellipharmaceutics International's stock symbol?

Intellipharmaceutics International trades on the OTCMKTS under the ticker symbol "IPCIF."

How do I buy shares of Intellipharmaceutics International?

Shares of IPCIF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellipharmaceutics International's stock price today?

One share of IPCIF stock can currently be purchased for approximately $0.17.

How much money does Intellipharmaceutics International make?

Intellipharmaceutics International has a market capitalization of $5.50 million and generates $1.40 million in revenue each year. The company earns $-3.39 million in net income (profit) each year or ($0.19) on an earnings per share basis.

How many employees does Intellipharmaceutics International have?

Intellipharmaceutics International employs 13 workers across the globe.

What is Intellipharmaceutics International's official website?

The official website for Intellipharmaceutics International is www.intellipharmaceutics.com.

Where are Intellipharmaceutics International's headquarters?

Intellipharmaceutics International is headquartered at 30 WORCESTER ROAD, TORONTO A6, M9W 5X2.

How can I contact Intellipharmaceutics International?

Intellipharmaceutics International's mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001, via email at [email protected], or via fax at 416-798-3007.


This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.